Tenaya Therapeutics, Inc. (TNYA)
Largest Insider Buys in Sector
TNYA Stock Price History Chart
TNYA Stock Performance
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart …
Insider Activity of Tenaya Therapeutics, Inc.
Over the last 12 months, insiders at Tenaya Therapeutics, Inc. have bought $20M and sold $247,959 worth of Tenaya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tenaya Therapeutics, Inc. have bought $37.23M and sold $122,380 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GOEDDEL DAVID V () — $20M. COLUMN GROUP III GP, LP (10 percent owner) — $10M.
The last purchase of 2,222,222 shares for transaction amount of $10M was made by GOEDDEL DAVID V () on 2024‑02‑12.
List of Insider Buy and Sell Transactions, Tenaya Therapeutics, Inc.
| 2024-08-16 | Sale | Chief Executive Officer | 9,748 0.0131% | $2.89 | $28,216 | +1.92% | ||
| 2024-08-16 | Sale | Chief Medical Officer | 7,428 0.01% | $2.89 | $21,500 | +1.92% | ||
| 2024-08-16 | Sale | SVP, Accounting and Fin. Ops. | 2,363 0.0032% | $2.89 | $6,840 | 0.00% | ||
| 2024-03-05 | Sale | Chief Scientific Officer | 3,300 0.0044% | $7.00 | $23,101 | -45.66% | ||
| 2024-02-20 | Sale | Chief Scientific Officer | 6,569 0.0087% | $5.34 | $35,046 | -27.39% | ||
| 2024-02-16 | Sale | Chief Scientific Officer | 4,681 0.0064% | $5.86 | $27,431 | -39.72% | ||
| 2024-02-16 | Sale | Chief Executive Officer | 6,358 0.0087% | $5.86 | $37,258 | -39.72% | ||
| 2024-02-16 | Sale | Chief Medical Officer | 6,500 0.0088% | $5.86 | $38,090 | -39.72% | ||
| 2024-02-16 | Sale | Chief Fin. and Bus. Officer | 5,201 0.0071% | $5.86 | $30,478 | -39.72% | ||
| 2024-02-12 | 2.22M 2.6767% | $4.50 | $10M | -29.86% | ||||
| 2024-02-12 | 10 percent owner | 2.22M 2.6767% | $4.50 | $10M | -29.86% | |||
| 2023-08-29 | Sale | Chief Scientific Officer | 7,243 0.0111% | $4.26 | $30,855 | -18.16% | ||
| 2023-08-16 | Sale | Chief Scientific Officer | 4,007 0.0059% | $3.81 | $15,267 | -4.43% | ||
| 2023-08-16 | Sale | Chief Executive Officer | 5,563 0.0083% | $3.81 | $21,195 | -4.43% | ||
| 2023-08-16 | Sale | Chief Medical Officer | 5,563 0.0083% | $3.81 | $21,195 | -4.43% | ||
| 2023-08-16 | Sale | Chief Fin. and Bus. Officer | 4,452 0.0066% | $3.81 | $16,962 | -4.43% | ||
| 2023-03-10 | 6,779 0.0092% | $2.60 | $17,596 | +47.13% | ||||
| 2023-03-10 | 10 percent owner | 6,779 0.0092% | $2.60 | $17,596 | +47.13% | |||
| 2023-02-08 | 1.5M 1.9331% | $2.60 | $3.9M | +16.12% | ||||
| 2023-02-08 | 10 percent owner | 1.5M 1.9331% | $2.60 | $3.9M | +16.12% |
Insider Historical Profitability
| GOEDDEL DAVID V | 13599275 17.2385% | $2.25 | 7 | 0 | +27.92% | |
| COLUMN GROUP III GP, LP | 10 percent owner | 13599275 17.2385% | $2.25 | 7 | 0 | +27.92% |
| Casdin Eli | director | 6078860 7.7056% | $2.25 | 2 | 0 | <0.0001% |
| Casdin Partners Master Fund, L.P. | 10 percent owner | 3224849 4.0878% | $2.25 | 1 | 0 | <0.0001% |
| Srivastava Deepak | director | 372435 0.4721% | $2.25 | 1 | 0 | +31.12% |
Institutional Investor Ownership
| Column Group Llc | $49.16M | 11.97 | 9.4M | 0% | +$0 | 37.33 | |
| Casdin Capital | $35.21M | 8.57 | 6.73M | +5.51% | +$1.84M | 1.74 | |
| RA Capital Management, L.P. | $30.1M | 7.33 | 5.76M | +4.5% | +$1.3M | 0.03 | |
| BlackRock | $24.59M | 5.99 | 4.7M | +24.14% | +$4.78M | <0.01 | |
| T. Rowe Price | $17.5M | 4.26 | 3.35M | -26.36% | -$6.27M | <0.01 |